ReVance Therapeutics, Inc. Scores $33 Million in Series E Financing
4/2/2013 6:57:08 AM
More...
|
ReVance Therapeutics, Inc. Settles With Medicis (MRX) for Up to $25 Million, Regains Global Rights to Botulinum Toxin Products
10/8/2012 7:20:29 AM
More...
|
ReVance Therapeutics, Inc. Announces $45 Million Financing
6/10/2011 6:34:57 AM
More...
|
ReVance Therapeutics, Inc. Announces Clinical Trial Results of RT001 Topical Gel Presented at the Annual Meeting of the American Society for Dermatologic Surgery
10/25/2010 12:05:39 PM
More...
|
ReVance Therapeutics, Inc. (JOBS) Raises $25 Million
12/28/2009 8:21:49 AM
More...
|
Medicis (MRX) and ReVance Therapeutics, Inc. Announce Agreement for Development of Next-Gen Neurotoxin; Revance to Receive $10M and Additional Milestone Payments of $94M
7/29/2009 7:34:06 AM
More...
|
ReVance Therapeutics, Inc. Levers Up with $8 Million Financing
11/18/2008 8:11:52 AM
More...
|
ReVance Therapeutics, Inc. Announces Additional $8M Series C Expansion
5/12/2008 10:13:26 AM
More...
|
Medicis (MRX) and ReVance Therapeutics, Inc. Announce Strategic Collaboration
12/12/2007 8:52:34 AM
More...
|
ReVance Therapeutics, Inc. Announces Initiation Of Phase Ib Clinical Trial Of Topically Applied Botulinum Toxin Type A Gel For The Treatment Of Facial Aesthetics
11/9/2006 11:37:49 AM
More...
|
|